ClinicalTrials.gg
CompletedNCT03687554Updated Apr 25, 2022

Effect of Venglustat in Patients With Renal Impairment

A Phase 1 interventional study of Venglustat GZ/SAR402671 in Healthy Volunteers and Polycystic Kidney, Autosomal Dominant, sponsored by Genzyme, a Sanofi Company. Completed at 1 site in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2019, 7 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States — 14 open to participants now, 25 under way, 1 of them phase 3. Polycystic Kidney, Autosomal Dominant · United States.

Enrollment
47th of 63
24 · median 48
Started
2018
with 5 others
Phase 1
10 of 85
2 open now
Registered
45th of 85
by date
Lead sponsor
2 of 85
Genzyme, a Sanofi Company

Among the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, this one is the 47th largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2018, is one of 10 in phase 1, and was the 45th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

14 of the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, or all of them as a file.
02

Study summary

Primary Objective:

To study the effect of mild, moderate and severe renal impairment on the pharmacokinetics (PK) of Venglustat following a single dose.

Secondary Objective:

To assess the tolerability of Venglustat given as a single dose in subjects with mild, moderate and severe renal impairment in comparison with matched subjects with normal renal function.

Read the detailed description

Approximately 41 days, including a 21-day screening period, a 1-day treatment period, followed by a 9-day period of plasma sampling for assessment of primary endpoints.

03

Conditions studied

  • Healthy Volunteers
  • Polycystic Kidney, Autosomal Dominant
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For all Subjects:

  • Male and/or female subjects, between 18 and 79 years of age, inclusive.
  • Body weight between 50.0 and 115.0 kg, inclusive, if male, and between 40.0 and 100.0 kg, inclusive, if female, between 18.0 and 34.9 kg/m2, inclusive
  • Normal (ECG)
  • Having given written prior to undertaking any study-related procedure
  • Not under any administrative or legal supervision
  • Male subject, whose partners are of (including lactating women), must accept to use, during sexual intercourse, a double method according to the following algorithm: (condom) plus (spermicide or intra-uterine device or hormonal contraceptive) from the inclusion up to 4 months after the last dosing
  • Male subject, whose partners are pregnant, must use, during sexual intercourse, a condom from the inclusion up to 4 months after the last dosing
  • Male subject has agreed not to donate sperm from the inclusion up to 4 months after the last dosing
  • Female subject must use a double contraception method including a highly effective method of birth control from at least 30 days prior to the inclusion to 30 days after the last IMP administration, except if she has undergone sterilization (documented) at least 3 months earlier or is

Specific for subjects with renal impairment:

  • Stable chronic renal impairment
  • Vital signs and laboratory parameters within acceptable range for subjects with renal impairment

Specific for matched healthy subjects:

  • Normal renal function
  • Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical exam)
  • Normal vital signs and laboratory parameters

Exclusion criteria

Exclusion criteria:

  • Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month)
  • Blood donation, any volume, within 2 months before inclusion
  • Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension judged by the Investigator
  • Any significant change in chronic treatment medication within 14 days before inclusion
  • Any drug which could impact by any mechanism of action, the pharmacokinetics of the medicinal product, including moderate and strong cytochrome P3A () inhibitors or inducers; any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion
  • Positive result on any of the following tests: surface (HBs Ag) antigen, anti- virus (anti-HCV) antibodies, anti- 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab)
  • Positive result on urine drug screen or plasma alcohol test
  • Active hepatitis, hepatic insufficiency
  • If female, pregnancy [defined as positive β-Human Chorionic Gonadotropin (β-HCG) blood test], breast-feeding

Specific for subjects with renal impairment:

  • Uncontrolled clinically relevant cardiovascular, pulmonary, gastrointestinal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness
  • Acute renal failure (de novo or superimposed on preexisting chronic renal impairment), nephrotic syndrome
  • History of or current hematuria of urologic origin that limits the subject's participation in the study
  • Subjects requiring dialysis during the study

Specific for matched healthy controls:

- Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female) or infectious disease, or signs of acute illness

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Venglustat

    Single dose of Venglustat is given, orally under fasting conditions

    Drug: Venglustat GZ/SAR402671

Interventions

  • DrugVenglustat GZ/SAR402671

    Pharmaceutical form: Hard Capsule Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Assessment of pharmacokinetic (PK) parameters of Venglustat: Area under the curve (AUC)

    Venglustat area under the plasma concentration versus time curve (AUC)

    Time frame: Day 1 to Day 10

Secondary outcomes

  1. Venglustat plasma pharmacokinetic (PK) parameter: Cmax

    Maximum plasma concentration observed (Cmax)

    Time frame: Day 1

  2. Venglustat plasma pharmacokinetic (PK) parameter: AUClast

    Area under the plasma concentration versus time curve calculated from time zero to the real time tlast (AUClast)

    Time frame: Day 1 to Day 10

  3. Venglustat plasma pharmacokinetic (PK) parameter: unbound Cmax

    Maximum plasma concentration observed of unbound drug (unbound Cmax)

    Time frame: Day 1 to Day 10

  4. Venglustat plasma pharmacokinetic (PK) parameter: unbound AUC

    Change in unbound Venglustat area under the plasma concentration versus time curve (unbound AUC)

    Time frame: Day 1 to Day 10

  5. Venglustat plasma pharmacokinetic (PK) parameter: CL/F

    Apparent total body clearance of Venglustat from plasma (CL/F)

    Time frame: Day 1 to Day 10

  6. Venglustat plasma pharmacokinetic (PK) parameter: Vss/F

    Apparent volume of distribution of Venglustat at steady state (Vss/F)

    Time frame: Day 1 to Day 10

  7. Venglustat plasma pharmacokinetic (PK) parameter: fu

    Fraction of unbound venglustat in plasma (fu)

    Time frame: Day 1 to Day 10

  8. Venglustat plasma pharmacokinetic (PK) parameter: t1/2z

    Terminal half-life associated with the terminal slope (t1/2z)

    Time frame: Day 1 to Day 10

  9. Venglustat plasma pharmacokinetic (PK) parameter: t1/2eff

    Effective half-life (t1/2eff)

    Time frame: Day 1 to Day 10

  10. Venglustat urine pharmacokinetic (PK) parameter: Ae(0-24)

    Cumulated amount excreted in urine from time 0 to time 24h after Venglustat administration

    Time frame: Day 1 and Day 2

  11. Venglustat urine pharmacokinetic (PK) parameter: fe(0-24)

    Fraction of dose excreted in urine from time 0 to time 24h after Venglustat administration

    Time frame: Day 1 and Day 2

  12. Venglustat urine pharmacokinetic (PK) parameter: CLR(0-24)

    Renal clearance of the drug determined in the 0-24h interval (CLR(0-24))

    Time frame: Day 1 and Day 2

  13. Venglustat plasma pharmacokinetic (PK) parameter: Rac,pred

    Predicted accumulation ratio (Rac,pred)

    Time frame: Day 1 to Day 10

07

Study locations

1 site
  • Investigational Site Number 8400001
    Miami, Florida 33014, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Feb 2019, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2018
First posted
Sep 27, 2018
StartActual
Oct 5, 2018
Primary completionActual
Feb 27, 2019
CompletionActual
Feb 27, 2019
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03687554
Responsible party
Sponsor
First posted
Sep 27, 2018
Start date
Oct 5, 2018
Primary completion
Feb 27, 2019
Completion
Feb 27, 2019
Last update
Apr 25, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion